Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W N Deininger

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Haematologica|April 12, 2005
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signaturesLucy C Crossman, Motomi Mori, Yi-Ching Hsieh, et al.
Blood|July 10, 2004
Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesisIan J Griswold, Lei J Shen, Paul La Rosée, et al.
Blood|December 17, 2008
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patientsJeffrey W Tyner, Heidi Erickson, Michael W N Deininger, et al.
Cancer Research|June 3, 2005
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutantsThomas O'Hare, Denise K Walters, Eric P Stoffregen, et al.
Cancer Research|April 21, 2011
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profileChristopher A Eide, Lauren T Adrian, Jeffrey W Tyner, et al.
Blood|March 5, 2005
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of KitAmie S Corbin, Shadmehr Demehri, Ian J Griswold, et al.
Cancer|August 19, 2007
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cellsMichael W N Deininger, Jorge Cortes, Ron Paquette, et al.
Blood|May 17, 2003
Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletionsBrian J P Huntly, Francois Guilhot, Alistair G Reid, et al.
JAMA Network Open|December 18, 2023
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid LeukemiaAaron N Winn, Ehab Atallah, Jorge Cortes, et al.
Blood Advances|February 23, 2018
Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemiaTibor J Kovacsovics, Alice Mims, Mohamed E Salama, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Haematologica|April 12, 2005
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signaturesLucy C Crossman, Motomi Mori, Yi-Ching Hsieh, et al.
Blood|July 10, 2004
Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesisIan J Griswold, Lei J Shen, Paul La Rosée, et al.
Blood|December 17, 2008
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patientsJeffrey W Tyner, Heidi Erickson, Michael W N Deininger, et al.
Cancer Research|June 3, 2005
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutantsThomas O'Hare, Denise K Walters, Eric P Stoffregen, et al.
Cancer Research|April 21, 2011
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profileChristopher A Eide, Lauren T Adrian, Jeffrey W Tyner, et al.
Blood|March 5, 2005
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of KitAmie S Corbin, Shadmehr Demehri, Ian J Griswold, et al.
Cancer|August 19, 2007
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cellsMichael W N Deininger, Jorge Cortes, Ron Paquette, et al.
Blood|May 17, 2003
Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletionsBrian J P Huntly, Francois Guilhot, Alistair G Reid, et al.
JAMA Network Open|December 18, 2023
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid LeukemiaAaron N Winn, Ehab Atallah, Jorge Cortes, et al.
Blood Advances|February 23, 2018
Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemiaTibor J Kovacsovics, Alice Mims, Mohamed E Salama, et al.
Pageof 6